SCHEMBL6624196

SCHEMBL6624196

COC(=O)[C@@H]1CC(O[Si](C)(C)C(C)(C)C)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 2/20 0.40
UCHL1 P09936 1/20 0.38
NR1H2 P55055 2/20 0.37
NR1H3 Q13133 1/20 0.37
MMP2 P08253 3/20 0.37
ANPEP P15144 3/20 0.37
PTPN1 P18031 1/20 0.36
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
CCR2 P41597 1/20 0.32
CCNT1 O60563 1/20 0.32
CDK9 P50750 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
HTRA1 Q92743 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7456999 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL142967 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL18577311 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL1269514 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL2387781 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL24826391 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL1269513 1.00 P2RX3 (0.40) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL29548437 0.92 UCHL1 (0.37) P2RX3UCHL1NR1H2CYP1A2POLB
SCHEMBL28567716 0.90 P2RX3 (0.41) P2RX3UCHL1NR1H2NR1H3MMP2
SCHEMBL24998822 0.90 P2RX3 (0.41) P2RX3UCHL1NR1H2NR1H3MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106362-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2025-05-22 WO disclosed
US-11236046-B2 Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators GENENTECH, INC. (US) 2022-02-01 US disclosed
EP-3497093-B1 SULFONYL PYRIDYL TRP INHIBITORS HOFFMANN LA ROCHE (CH) 2021-09-15 EP disclosed
US-11028095-B2 Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-06-08 US disclosed
US-10695348-B2 Sulfonyl pyridyl TRP inhibitors GENENTECH, INC. (US) 2020-06-30 US disclosed
US-20200181159-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2020-06-11 US disclosed
US-20200048197-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2020-02-13 US disclosed
EP-3256463-B1 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2019-10-09 EP disclosed
WO-2019164778-A1 PROCESS FOR PREPARING 1-ARYLSULFONYL-PYRROLIDINE-2-CARBOXAMIDE TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST COMPOUNDS AND CRYSTALLINE FORMS THEREOF GENENTECH, INC. (US) 2019-08-29 WO disclosed
US-20190167681-A1 SULFONYL PYRIDYL TRP INHIBITORS GENENTECH, INC. (US) 2019-06-06 US disclosed
US-20180118680-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2018-05-03 US disclosed
WO-2018029288-A1 SULFONYL PYRIDYL TRP INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-02-15 WO disclosed
WO-2018026792-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC. (US) 2018-02-08 WO disclosed
US-8263549-B2 C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2012-09-11 US disclosed
US-8030307-B2 Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease ENANTA PHARMACEUTICALS, INC. (US) 2011-10-04 US disclosed
US-20090175822-A1 C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2009-07-09 US disclosed
EP-0986384-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 2004-09-15 EP disclosed
US-6310095-B1 INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE UNIVERSITY OF PITTSBURGH 2001-10-30 US disclosed
EP-0986384-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 2000-03-22 EP disclosed
WO-1998050029-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10695348-B2 Sulfonyl pyridyl TRP inhibitors TRPA1, TRPV1, TRPV5 P2RX3 13/4885UCHL1 4431/4885NR1H2 2472/4885
US-20180118680-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 P2RX3 26/4885UCHL1 4468/4885NR1H2 1224/4885
US-20190167681-A1 SULFONYL PYRIDYL TRP INHIBITORS TRPA1, TRPV1, TRPV5 P2RX3 13/4885UCHL1 4431/4885NR1H2 2472/4885
US-20200181159-A1 SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN2C P2RX3 2328/4885UCHL1 4096/4885NR1H2 394/4885
US-20090175822-A1 C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS PREP, PRSS1, CTSC P2RX3 2056/4885UCHL1 1189/4885NR1H2 1798/4885
US-20200048197-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 P2RX3 26/4885UCHL1 4468/4885NR1H2 1224/4885
US-11028095-B2 Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN2C P2RX3 2328/4885UCHL1 4096/4885NR1H2 394/4885
US-11236046-B2 Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators TRPA1, TRPV1, TRPV2 P2RX3 26/4885UCHL1 4468/4885NR1H2 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.